Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
Authors:
- Matilde ZaballosMatilde Zaballos
- Mercedes PowerMPMercedes Power
- María Iluminada Canal-AlonsoMCMaría Iluminada Canal-Alonso
- María Ángeles González-NicolásMGMaría Ángeles González-Nicolás
- Wenceslao Vasquez-JimenezWVWenceslao Vasquez-Jimenez
- Pablo Lozano-LomincharPLPablo Lozano-Lominchar
- Pilar Cabrerizo-TorrentePCPilar Cabrerizo-Torrente
- Natividad Palencia-GarcíaNPNatividad Palencia-García
- Susana Gago-QuirogaSGSusana Gago-Quiroga
- María Dolores Ginel-FeitoMGMaría Dolores Ginel-Feito
- Consuelo JiménezCJConsuelo Jiménez
- Alberto LázaroALAlberto Lázaro
Open Access
- 27 January 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (3) , 1239
Abstract
Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC-cisplatin). Prophylaxis was with imipenem/cilastatin. Cilastatin is a selective inhibitor of renal dehydropeptidase I in the proximal renal tubule cells that can reduce the nephrotoxicity of cisplatin. Unfortunately, cilastatin is not currently marketed alone, and can only be administered in combination with imipenem. The study has a retrospective part that serves as a control (n = 99 patients receiving standard surgical prophylaxis) and a prospective part with imipenem/cilastatin prophylaxis corresponding to the study group (n = 85 patients). In both groups, we collected specific data on preoperative risk factors of renal damage, fluid management, hemodynamic control, and urine volume during surgery (including the hyperthermic chemotherapy perfusion), as well as data on hemodynamic and renal function during the first seven days after surgery. The main finding of the study is that cilastatin may exert a nephroprotective effect in patients with peritoneal carcinomatosis undergoing cytoreduction and hyperthermic intraperitoneal cisplatin perfusion. Creatinine values remained lower than in the control group (ANOVA test, p = 0.037). This translates into easier management of these patients in the postoperative period, with significantly shorter intensive care unit (ICU) and hospital stay.Keywords
Funding Information
- Instituto de Salud Carlos III (PI11/01132, PI14/01195, PI17/00276 cofinanced by FEDER Funds from the European Comission "A way of making Europe", REDinREN/RD16/0009/0026)
- Comunidad de Madrid (S2017-BMD-3686 (CIFRA2-CM))
- Fundación Senefro (Nephrology research grant SENEFRO 18/01)
- Fundación Mutua Madrileña (Research grant 2020)
This publication has 56 references indexed in Scilit:
- Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in ratsKidney International, 2012
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative BacteriaAnnual Review of Microbiology, 2011
- Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French StudyJournal of Clinical Oncology, 2010
- Hyperthermic intraperitoneal chemotherapy: Rationale and techniqueWorld Journal of Gastrointestinal Oncology, 2010
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Critical Analysis of Treatment Failure After Complete Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Dissemination From Appendiceal Mucinous NeoplasmsAnnals of Surgical Oncology, 2007
- Acute Renal Disease, as Defined by the RIFLE Criteria, Post-Liver TransplantationAmerican Journal of Transplantation, 2006
- Role of early plasma membrane events in chemotherapy-induced cell deathDrug Resistance Updates, 2005
- Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cellsNephrology Dialysis Transplantation, 2004
- REDUCTION OF CYCLOSPORINE-INDUCED NEPHROTOXICITY BY CILASTATIN FOLLOWING CLINICAL HEART TRANSPLANTATION1Transplantation, 1994